Hims & Hers partners with Novo Nordisk to sell Wegovy and Ozempic, ending dispute
Hims & Hers partners with Novo Nordisk to sell Wegovy and Ozempic, ending dispute Proactive uses images sourced…
Novo Nordisk & Hims & Hers Deal: Wegovy, Ozempic Sales on Platform – News and Statistics
Mar 9, 2026 According to a report from Yahoo Finance, Novo Nordisk has agreed to dismiss a patent…
HIMS Stock Soars After Novo Nordisk Drops Patent Infringement Lawsuit, Opens Access To Ozempic, Wegovy
Hims & Hers also stated that it will no longer advertise compounded GLP-1 offerings on its platform or…
Novo Nordisk, Hims & Hers settle GLP-1 drug dispute
Listen to this article The basics: Novo Nordisk and Hims & Hers have ended a legal feud with…
Novo Nordisk to Sell Weight-Loss Drugs Through Hims & Hers
Hims & Hers will offer access to the Wegovy obesity drug in injection and pill forms. – Novo…
The era of $199 copycat weight loss drugs is ending — and it could cost patients
After two splashy Super Bowl commercials focused on making weight loss medication more accessible, Hims & Hers will…
Hims & Hers & Novo Nordisk Partner for Ozempic, Wegovy Sales | 2026 – News and Statistics
Mar 9, 2026 According to a report from Investopedia, shares of Hims & Hers Health experienced a significant…
Novo Nordisk expands U.S. patient access to FDA-approved semaglutide medicines through Hims & Hers
Novo Nordisk today announced it has reached an agreement with telehealth company Hims & Hers that will take…
Hims & Hers, Novo Nordisk Strike GLP-1 Deal Weeks After Lawsuit
Shares of Hims & Hers surged after the company announced it was partnering — again — with the…
Novo Nordisk, Hims to sell obesity drugs together
Danish drugmaker Novo Nordisk plans to sell its obesity treatments through the platform of Hims & Hers Health,…
Novo Nordisk sues Hims for GLP-1 patent infringement
[Adobe Stock] Imitation is the sincerest form of flattery, some say. Novo Nordisk would probably disagree. Copycats of…
Novo Nordisk’s Legal Battle Over Wegovy Compounded Versions
Novo Nordisk’s Patent Lawsuit Overview By Blake Brittain Background of the Case Feb 10 (Reuters) – Novo Nordisk’s…